– Cloud Practice offers cloud-based electronic medical records software applications for physicians throughout Canada
– As per the latest reported financials, Cloud Practice is EBITDA positive, resulting in immediate cash flow generation and earnings accretion for Premier Health
– Products include: Juno EMR, a cloud-based EMR solution; ClinicAid, a medical billing software; and MyHealthAccess, an online patient portal
– Juno EMR system is currently used by 287 clinics, over 3,000 licensed practitioners, 1,500 staff and 2,870,000 registered patients
– ClinicAid processes upwards of $30,000,000 in payments to over 3000 health providers on a monthly basis
– Cloud Practice’s founders, including CEO Jordan Visco , and entire support team, consisting of several software developers and sales staff, to join Premier
VANCOUVER , Dec. 17, 2018 /CNW/ – Premier Health Group Inc. (PHGI.CN), (PHGI.CN), (PHGRF), (Frankfurt:6PH), (6PH.F) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to announce that as a part of its technology platform, it has signed a binding LOI to acquire all of the outstanding securities of Cloud Practice Inc. (“Cloud Practice”).
Dr. Essam Hamza , CEO of Premier Health, said: “We are ecstatic at the opportunity to build on our patient centric technology platform through the integration of Cloud Practice’s suite of software solutions. They have a strong team of developers who are just as enthusiastic as we are about the future of healthcare. We believe that this partnership will help facilitate our vision of integrating telemedicine, online booking and other premium services with our electronic medical record (EMR) system.”
Dr. Essam continued: “Cloud Practice already has a tremendous standalone and growing business serving thousands of clinicians and millions of patients. The collective ecosystem of over 3,000,000 patients creates an opportunity to become a key player in the telehealth space in Canada .”
Jordan Visco , CEO of Cloud Practice, stated: “We are very excited to be joining a forward-thinking group such as Premier Health. The synergies between our two teams will help enable us to better streamline processes, making healthcare more efficient for all. We are also excited to implement some upcoming new, leading edge applications to make our software the best in the industry.”
Terms of the Acquisition
In consideration for the purchase of all of the outstanding Cloud Practice securities, Premier will pay to the Cloud Practice shareholders total consideration of up to $5 million as follows: (i) $500,000 paid in cash on signing of the binding LOI as a refundable deposit, (ii) $500,000 in cash payable on closing, (iii) $500,000 in cash payable 90 days after closing, (iv) $500,000 in cash payable within six months of the LOI subject to the satisfaction of certain milestones related to the integration of the Juno EMR, and (v) an aggregate of $3 million payable in commons shares of Premier at a price to be determined in the context of the market.
The acquisition is subject to customary closing conditions, including the execution of a definitive acquisition agreement and receipt of Canadian Securities Exchange approval. Closing is expected to occur at or about the end of December.
ON BEHALF OF THE BOARD OF DIRECTORS
Dr. Essam Hamza , MD
Chief Executive Officer
About Premier Health
Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. We are developing innovative health care approaches that combine human skill-based expertise with emerging technologies, with the goal of setting the gold standard for services in locations of interest worldwide. Premier Health’s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally. The HealthVue team has a strong track record of successfully creating value in healthcare and technology enterprises. The Management team has deep clinical, financial and operational expertise and a passion for improving healthcare for all patients.
About Cloud Practice
Cloud Practice is a cloud-based software solutions company focused on streamlining medical practice throughout Canada . They offer three products including Juno EMR, ClinicAid and MyHealthAccess. Juno EMR, a modified branch of an open-source electronic medical records (EMR) software which was originally released by McMaster University , is hosted in the cloud and can be accessed anywhere, anytime. ClinicAid is Canada’s easiest medical billing software. MyHealthAccess is an online patient portal which puts patients back in control of their health care through connecting with their clinics and booking appointments online.
This news release contains forward-looking statements that are based on Premier Health’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans, completion of its acquisition of Cloud Practice, and the timing thereof, the expected benefits to the Company following the integration of Cloud Practice’s software and the expected implementation of new applications, including the timing thereof, the expect growth to Cloud Practice’s business and the expected synergies resulting from the Company’s acquisition of Cloud Practice. Although Premier Health believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and Premier Health undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
This news release contains references to EBITDA, which is a non-IFRS metric. EBITDA is defined as earnings before interest, taxes, depreciation and amortization. Premier uses EBITDA as it is a common measure used to assess profitability before the impact of interest expense, income taxes, depreciation and impairment of capital assets and amortization of intangible assets. Premier believes that investors and financial analysts also use EBITDA to evaluate financial performance. EBITDA is not a measure of financial performance under IFRS and should not be considered as an alternative to operating income or any other measure of financial performance presented in accordance with IFRS. EBITDA excludes some, but not all, items that affect operating income.
SOURCE Premier Health Group Inc.
Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $300,000 ( CASH) for & were paid “500,000” shares of restricted common shares (as of 1/2/2019). We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 we plan to sell the “500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full disclaimer.
Biotech Names To Know In November 2019
Biotech Stocks Have rallied since The End Of September; What’s Next?
Over the years, the biotech sector has become one of the fastest-growing sectors in the stock market and naturally, investors are keen to get hold of stocks that could follow a similar growth trajectory. However, just because a sector is growing does not mean that an investor can bet on any stock and hope to make decent returns.
In order to choose the right stock, he needs to do a lot of personal research and watch the market closely. Here is a look at three biotech stocks that investors should track closely owing to recent developments.
Sernova Corp’s (TSX:SVA) (OTC:SEOVF)
Sernova’s therapeutic approach to regenerative medicine focuses on providing direct cell therapies where the cells, transplanted within an organ-like vascularized implantable device, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.
The company’s Cell Pouch is a novel, proprietary, scalable, implantable macro-encapsulation device designed for the long- term survival and function of therapeutic cells. At the end of October Sernova Corp. (SVA) (SEOVF) detected enduring levels of C-peptide in the bloodstream of a fasting patient in its continuing phase I/II Cell Pouch United States clinical study of type-1 diabetes. This C-peptide is a biomarker of transplanted beta-cell insulin production,
Why is this important? According to Dr. Piotr Witkowski, Director of Pancreatic, and Islet Transplant Program at the University of Chicago, “Along with the preliminary safety and early indicators of efficacy, I am excited that we are observing C-peptide levels in the patient’s bloodstream after recent transplant, not only following stimulation with a meal but also when the patient is fasting. These findings represent progress in clinical outcomes and evidence of enduring islet survival and function within Sernova’s Cell Pouch.”
The first one to put in the watch list is that of Genprex Inc (NASDAQ:GNPX). On Tuesday, the company revealed preclinical data from its study of its product TUSC2 immunogene therapy. The product in question is meant for raising the effectiveness of chemotherapy and anti-PD1 in people suffering from metastatic lung cancers.
The data proved to be positive and that has naturally resulted in a rally in the stock. It is a significant development for Genprex and could potentially help the company in cornering an important portion of the gene therapy market. Hence, it is hardly a surprise that the stock has rallied by as much as 60% after hitting a session’s high of $1.09.
Can Fite Biopharma (CANF)
The other biotech stock that has made a strong move is the Can Fite Biopharma (NYSE:CANF) stock. The biotech company announced this morning that one of its products, which is meant for the treatment of liver diseases and cancer, has been granted a patent as a sexual dysfunction medicine.
The patents have been granted by the relevant authorities in Canada, Israel, and South Korea. In addition to that, the company has also been awarded patents in Japan, China, United States, Australia, and Hong Kong. It is a highly important development for Can-Fite and it was no surprise when the stock rallied this morning. It has rallied by 3% on Tuesday on the back of the news.
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.
Is The Entertainment Streaming Market Ready For Its Next Move?
New Streaming Options Have Opened A Big Door For Content Providers
As many experts have pointed out, the end of 2019 is going to see the commencement of the ‘streaming wars’ as more and more companies enter the OTT market to challenge the supremacy of Netflix Inc (NASDAQ:NFLX). The launch of the streaming service Disney Plus last week formally launched the streaming wars.
Do Content Providers Stand To Benefit?
According to an article published on Reuters the global video streaming market was valued at $26.27 billion in 2015 and is expected to reach $83.41 billion by 2022 growing at a CAGR of 17.9% from 2015 to 2022. Apple, Disney, Netflix, Amazon, NBC, Hulu & more are all competing within the global video streaming market and they all need the same thing… new & original content. Massive demand may create a huge opportunity for companies like Fearless Films (FERL).
Fearless Films is an independent full-service production company. This is the exact type of company that can benefit from what could become one of the biggest cash grabs in entertainment history and here’s why. You’ve likely heard of the big production houses: Warner Bros, DreamWorks, Red Crown Productions and others who benefited from big deals with streaming companies.
It isn’t just Netflix who’s flexing billions in content budgets, Apple, Amazon, Disney, NBC, Roku – the list goes on. These are huge entertainment distributors who are now fighting for one thing… Where you spend your waking hours streaming entertainment.
Key Analysis On Streaming Service Providers
Considering the fact that the new service has already garnered 10 million users, it’s fair to say that it is here to say. Considering the fact that Apple has already launched its own service and many other services are going to be launched in the next few months, experts are now wondering whether the streaming space has become too crowded.
The success of Game of Thrones has ushered in an era of unprecedented spending for quality content. The show generated total profit to the tune of $2.2 billion for HBO, which is owned by AT&T. Hence, video streaming companies have also decided to spend jaw-dropping sums on original content. Apple has earmarked $6 billion for original content, while Disney is expected to match that.
Both companies are trying to create that one show that could turn into a cash cow. On the other hand, Apple is going to price is monthly subscription at $4.99 and Disney is going to charge $6.99 for the same. In such a situation, one can expect Netflix to change tack since its cheapest subscription is worth $12.99.
So, the crowding is quite apparent as mega corporations enter the streaming space. However, the question remains whether the business is going to grow and new subscribers are going to flock in. Studies suggest that it will grow and up until 2024, the streaming market should grow by 18.8% each year. In 2024, the market is going to be worth $687 billion. Hence, it is quite clear that despite the intense competition that is going to come to the streaming space, there is still room for companies to grow and become profitable.
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Fearless Films Inc. (FERL), Midam has been paid $94,980 by Fearless Films Inc. (FERL) for a period from October 1, 2019 to November 17, 2019. We may buy or sell additional shares of Fearless Films Inc. (FERL) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Fearless Films Inc. (FERL). Click Here For Full Disclaimer.
Stock Price Newsletter – November 20, 2019
The Biotech Index Just Hit New Highs; Stocks To Watch
Investment experts and professional money managers almost always tell people to invest across a range of experts. This is usually in order to generate bigger returns in the long term. One of the sectors that is almost always favored by professionals is the biotech sector and the simple reason behind that is the fact that the sector has managed to grow at an impressive pace.
What Does The Disney (DIS) Plus, Amazon Deal Mean For Investors?
During the company’s conference call for the fourth-quarter earnings, the Chief Executive Officer of Disney Bob Iger stated that the streaming serving Disney+ is going to be available on Amazon Fire TV.
The $40 Billion Dollar Content Gold Rush
Apple, Disney, Netflix, Amazon, NBC, Hulu & More are All Competing Within the Global Video Streaming Market and They All Need the Same Thing… New & Original Content! Massive Demand May Create Huge Opportunity for One Company!
Join Our Newsletter
Get stock alerts, news & trending stock alerts straight to your inbox!
We keep all user information pricate & promise to never spam.*
Search Stock Price (StockPrice.com)
Featured2 weeks ago
3 Biotech Stocks to Watch Before Thanksgiving
Biotechnology1 week ago
3 Biotech Stocks to Watch After Key, 4th Quarter Developments
Biotechnology1 week ago
Biotech Stocks To Watch This Week
Biotechnology2 weeks ago
3 Biotech Stocks To Watch Now After Big Market News
Biotechnology3 days ago
PharmaCyte Biotech (PMCB) Successfully Completes Final Manufacturing Run of Clinical Trial Product
Featured1 week ago
3 Biotechnology Stocks To Know Before 2020
Biotechnology6 days ago
3 Biotech Stocks To Watch As The Sector Heats Up
Biotechnology1 day ago
The Biotech Index Just Hit New Highs; Stocks To Watch